Skip to main content
COFCO BIOTECHNOLOGY CO., LTD. logo

COFCO BIOTECHNOLOGY CO., LTD. — Investor Relations & Filings

Ticker · 000930 ISIN · CNE000000ZR7 LEI · 300300CSR7RNP1P1CP32 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,252 across all filing types
Latest filing 2018-10-24 M&A Activity
Country CN China
Listing Shenzhen Stock Exchange 000930

About COFCO BIOTECHNOLOGY CO., LTD.

https://www.cofcotech.com

COFCO Biotechnology Co., Ltd. specializes in the deep processing of agricultural products, primarily corn, cassava, and other grains. The company operates as a major producer of fuel ethanol, edible alcohol, and starch-based products. Its portfolio includes a wide range of sweeteners such as fructose and glucose, as well as organic acids like citric acid and lactic acid. Additionally, the firm develops bio-based materials and biochemical products including amino acids and feed additives. Serving diverse sectors such as food and beverage, pharmaceuticals, and renewable energy, the company focuses on technological innovation in biotechnology to enhance resource efficiency and promote sustainable industrial applications. It maintains a significant presence in the global supply chain for bio-based chemicals and ingredients.

Recent filings

Filing Released Lang Actions
东兴证券股份有限公司关于公司收购报告书之财务顾问核查意见
M&A Activity Classification · 95% confidence The document is titled as a "收购报告书之财务顾问核查意见" which translates to "Acquisition Report - Financial Advisor's Verification Opinion." It is issued by Dongxing Securities as the financial advisor for the acquisition of COFCO Biochemical (Anhui) Co., Ltd. The content includes detailed sections about the acquirer, the acquisition plan, legal and regulatory compliance, financial data, and the financial advisor's opinions and commitments. The document references relevant Chinese laws and regulations governing acquisitions and securities, and it is a comprehensive report related to a corporate acquisition transaction. This type of document is characteristic of filings related to merger and acquisition activities, specifically an acquisition report with financial advisor verification. It is not an annual report, earnings release, or a simple announcement. Therefore, the appropriate classification is related to M&A activity.
2018-10-24 Chinese
关于COFCO Bio-chemical Investment Co.,Ltd免于提交豁免要约收购申请之法律意见书
Capital/Financing Update Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding a specific transaction involving COFCO Bio-chemical Investment Co., Ltd. It discusses the legal compliance and approvals related to a share issuance for asset purchase, including references to Chinese securities laws, company law, and regulatory approvals. The document focuses on the exemption from submitting a mandatory tender offer application under the relevant acquisition regulations. It is not a financial report, earnings release, or management discussion, but a legal opinion related to a capital transaction and regulatory compliance. This fits best under the category of Capital/Financing Update (CAP), as it provides detailed legal and procedural information about a financing transaction involving issuance of shares for asset acquisition and related approvals.
2018-10-24 Chinese
关于发行股份购买资产暨关联交易报告书的修订说明
Regulatory Filings Classification · 95% confidence The document is titled as a "修订说明" (Revision Explanation) related to a "发行股份购买资产暨关联交易报告书" (Report on Issuance of Shares to Purchase Assets and Related Party Transactions). It references approvals from the China Securities Regulatory Commission (CSRC) and details revisions made to a previously disclosed restructuring report. The content focuses on amendments and updates to a specific transaction report rather than presenting full financial statements or comprehensive financial performance data. The document length is short (1369 characters), and it primarily serves as an announcement or explanation of revisions to a report rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2018-10-24 Chinese
发行股份购买资产暨关联交易报告书摘要（修订稿）
Capital/Financing Update Classification · 95% confidence The document is a detailed report titled "发行股份购买资产暨关联交易报告书摘要（修订稿）" which translates to "Summary of the Report on Issuance of Shares to Purchase Assets and Related Party Transactions (Revised)". It involves a major asset acquisition by issuing shares, with extensive financial data, transaction details, valuation reports, audit references, and regulatory compliance information. The content includes detailed descriptions of the transaction background, pricing, approvals, and risk disclosures. This type of document is typical of a Capital/Financing Update (CAP) filing, as it provides comprehensive information about a company's financing activity involving issuance of shares to purchase assets and related party transactions. It is not an Annual Report, Audit Report, or Earnings Release, nor is it a simple announcement or proxy statement. The length and detail confirm it is the report itself, not just an announcement. Therefore, the correct classification is CAP.
2018-10-24 Chinese
关于发行股份购买资产暨关联交易事项获得中国证监会核准批复的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the approval from the China Securities Regulatory Commission (CSRC) for the issuance of shares to purchase assets, which is a capital raising and asset acquisition transaction. It details the approval conditions and the company's obligations to disclose further information and complete related procedures. There is no financial data or detailed report content, but rather a regulatory approval notice for a financing and asset purchase transaction. This fits the category of Capital/Financing Update (CAP). The document length is short and it is not a report publication announcement or certification. Therefore, the classification is CAP with high confidence.
2018-10-24 Chinese
关于《中粮生物化学（安徽）股份有限公司收购报告书》之法律意见书
Merger & Acquisition Classification · 95% confidence The document is a detailed legal opinion letter issued by a law firm regarding a major acquisition transaction involving COFCO Bio-chemical Investment Co., Ltd and COFCO Biochemical (Anhui) Co., Ltd. It references multiple regulatory frameworks and approvals from Chinese regulatory bodies such as the China Securities Regulatory Commission (CSRC), State-owned Assets Supervision and Administration Commission (SASAC), Ministry of Commerce, and Shenzhen Stock Exchange. The document discusses the issuance of shares to purchase assets, approval processes, shareholding structure changes, and detailed terms of the acquisition agreement. It is not a simple announcement but a comprehensive legal opinion related to a significant merger and acquisition transaction. The content aligns with filings related to merger and acquisition activities rather than general regulatory filings or announcements. Therefore, the most appropriate classification is Merger & Acquisition (MA).
2018-10-24 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.